Skip to main content
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc — Investor Relations & Filings

Ticker · PRLD ISIN · US74065P1012 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2022-11-14 Interim / Quarterly Rep…
Country US United States of America
Listing US PRLD

About Prelude Therapeutics Inc

https://preludetx.com/

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing innovative medicines for cancer patients with high unmet needs. The company's pipeline features small molecule therapies and leverages expertise in targeted protein degradation. Key development programs include highly selective KAT6A degraders for solid tumors, such as ER+ breast cancer, and mutant-selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms. Prelude is also advancing next-generation degrader antibody conjugates (DACs) with novel payloads. The company's science-driven approach targets critical cancer cell pathways to create potentially transformative treatments.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2022
2022-11-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text indicates that the company issued a press release announcing financial results for the quarter ended September 30, 2022, and attached an investor presentation. The document itself is not the earnings release but a report announcing the release of financial results and presentation materials. The length is 4072 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), as it is a current report announcing events and attaching materials, not the full earnings release or detailed financial report itself.
2022-11-14 English
10-Q
Interim / Quarterly Report Q2 2022
2022-08-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 9, 2022, reporting the issuance of a press release announcing financial results for the three months ended June 30, 2022. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is not deemed "filed" for certain regulatory purposes. The document itself is a current report announcing the earnings release, not the earnings release document itself. The length is 3684 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as an Earnings Release (ER) announcement, specifically the initial announcement of quarterly financial results.
2022-08-09 English
PRIMARY DOCUMENT
Director's Dealing
2022-06-22 English
PRIMARY DOCUMENT
Director's Dealing
2022-06-22 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.